Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBGI74)

Drug Name

ALX-0141 Drug Info

Synonyms

Nanobody therapeutic (bone disease), Ablynx; Nanobody therapeutic (osteoporosis), Ablynx

Indication

Disease Entry	ICD 11	Status	REF
Osteoporosis	FB83.0	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Osteoclast differentiation factor (ODF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Denosumab	DMNI0KO	Drug-induced osteoporosis		Approved	[3]
CEP-37251	DMYXQBF	Bone metastases	2D50	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Osteoclast differentiation factor (ODF)	TT9E8HR	TNF11_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031383)
2	Clinical pipeline report, company report or official report of Ablynx.
3	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4	This week in therapeutics Cancer. SciBX 3(40); doi:10.1038/scibx.2010.1202. Oct. 14, 2010